Skip to content

prospective and open multicenter randomize control study for enlarged lymphadenectomy of gastric cancer

prospective and open multicenter randomize control study for enlarged lymphadenectomy of gastric cancer

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001675
Enrollment
Unknown
Registered
2011-10-28
Start date
2012-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

experimental group:D2 Radical Gastrectomy plus Para-aortic Lymph Node Dissection

Sponsors

The First Affiliated Hospital Of The Sun-Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. the patient who has accepted the informed consent; 2. the patient whose age ranges from 18 to 65, either male or female; 3. the pathology of the patiet has confirmed the diagnosis of gastric cancer; 4. the CT and ultrasonic gastroscope of the patient has indicated stage T4 and/or the visible transfer to the lymphonodus beside the aorta abdominalis; 5. the patients doesn't need emergent operation; 6. ECOG health rating(PS)0-1.

Exclusion criteria

Exclusion criteria: 1. Pregnant woman and woman during lactation; 2. There's distant transfer to the liver, lung or bone; 3. There's involvement of the lymphoglandulae supraclaviculares, planting of the tumor in the pelvic cavity or on the ovarium, dissemination of the peritoneum; 4. plenty of ascites and dyscrasia has been found; 5. There's severe cardiovascular, respiratory, nephritic, hepatic disease or diabetes; 6. There's mental sickness; 7. The patient compliance is bad or the researcher expect there will not be good patient compliance; 8. The patient has some other clinical or laboratory situation that is not suitable for the trial according to the researcher's ajudgement.

Design outcomes

Primary

MeasureTime frame
overall survival rate;five-year survival rate;

Secondary

MeasureTime frame
no recurrence survival rate;mortality during the perioperative period;complication during the perioperative period;

Countries

China

Contacts

Public ContactYulong He
ylh@medmail.com.cn+86 13602839886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026